Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Benchmark Maintains Speculative Buy on Genelux, Lowers Price Target to $25

Author: Benzinga Newsdesk | May 31, 2024 11:12am
Benchmark analyst Bruce Jackson maintains Genelux (NASDAQ:GNLX) with a Speculative Buy and lowers the price target from $30 to $25.

Posted In: GNLX